Company intelligence / Profile preview

LinkingMed

Beijing, Beijing, Chinam.linkingmed.com ↗

Ownership: Private
Development stage: Commercial

Overview

LinkingMed has developed and commercialized an artificial intelligence-powered cloud platform that automates organ mapping, target mapping, radiotherapy plan generation, and quality control for cancer radiotherapy. The system is used by hospital radiotherapy departments and third-party imaging centers. In 2019, it received a Class III medical device license in China for its cloud-based product. No clinical trial results are reported as the product is a software tool rather than a therapeutic intervention.

Therapeutic areas: Oncology
Modalities: Non-pharmacological therapy (AI-driven radiotherapy planning and quality control)Device (software for medical devices/radiotherapy systems)
Industry: Digital Health Medical Devices

Partnerships

Intel (ecosystem partner)HospitalsThird-party imaging/radiotherapy centers

Beyond the preview

Go deeper on LinkingMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LinkingMed.

Explore the full profile